Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine.
Epidermal Growth Factor chemically conjugated to P64k carrier protein from Neisseria meningitidis emulsified in Montanide ISA 51 adjuvant is a cancer vaccine under clinical evaluation. We explored the influence of priming and boosting variables on the antibody response in mice. An apparently low dose fractionated in multiple anatomical sites at priming accelerated the induction and enhanced the maximal antibody response, with a long-lasting effect. Moreover, shortening the boosting time reduces the antibody persistence. Repeatedly boosting shift subjects to good antibody-responders, maintaining the epitope immunodominance. We conclude that optimizing immunopharmacological determinants contribute to an earlier, stronger and prolonged anti-EGF antibody persistence.
Rodriguez
Pedro C
PC
Experimental Immunotherapy Department, Center of Molecular Immunology, 216 Street & 15, Playa, P.O. Box 16040, Havana 11600, Cuba.
Gonzalez
Ileana
I
Gonzalez
Adys
A
Avellanet
Janet
J
Lopez
Armando
A
Perez
Rolando
R
Lage
Agustin
A
Montero
Enrique
E
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D004815:Epidermal Growth Factor / Q000276:immunology*; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008353:Mannitol / Q000008:administration & dosage / Q000031:analogs & derivatives; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009829:Oleic Acids / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D000912:Antibodies, Neoplasm; D001425:Bacterial Outer Membrane Proteins; D019496:Cancer Vaccines; D009829:Oleic Acids; C112623:lpdA protein, Neisseria meningitidis; C477385:montanide ISA 51; D008353:Mannitol; D004815:Epidermal Growth Factor